hERG: protein trafficking and potential for therapy and drug side effects.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current opinion in drug discovery & development

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 20047143
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative effects of sophocarpine and sophoridine on hERG K+ channel.

  2009cited by this paper
• Hypoxia inhibits maturation and trafficking of hERG K(+) channel protein: Role of Hsp90 and ROS.

  2009cited by this paper
• Blockade of HERG K+ channel by isoquinoline alkaloid neferine in the stable transfected HEK293 cells

  2009cited by this paper
• Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents

  2009cited by this paper
• Intracellular Potassium Stabilizes Human Ether-à-go-go-Related Gene Channels for Export from Endoplasmic Reticulum

  2009cited by this paper
• Literature‐based evaluation of four ‘hard endpoint’ models for assessing drug‐induced torsades de pointes liability

  2008cited by this paper
• Coexistence of hERG current block and disruption of protein trafficking in ketoconazole‐induced long QT syndrome

  2008cited by this paper
• Dose–response effects of sotalol on cardiovascular function in conscious, freely moving cynomolgus monkeys

  2008cited by this paper
• Rapid Kinetic Interactions of Ranolazine With HERG K+ Current

  2008cited by this paper
• Sensitive and reliable proarrhythmia in vivo animal models for predicting drug‐induced torsades de pointes in patients with remodelled hearts

  2008cited by this paper
• In vitro models of proarrhythmia

  2008cited by this paper
• Doxazosin induces apoptosis of cells expressing hERG K+ channels.

  2008cited by this paper
• The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys

  2008cited by this paper
• The QT syndromes: long and short.

  2008cited by this paper
• Strategies to reduce the risk of drug‐induced QT interval prolongation: a pharmaceutical company perspective

  2008cited by this paper
• Repolarization reserve: a moving target.

  2008cited by this paper
• Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines

  2008cited by this paper
• Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model

  2008cited by this paper
• HERG K+ channel blockade by the novel antiviral drug sophocarpine.

  2008cited by this paper
• In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.

  2008cited by this paper
• Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery

  2008cited by this paper
• Drugs and trafficking of ion channels: a new pro‐arrhythmic threat on the horizon?

  2008cited by this paper
• Predictive models for HERG channel blockers: ligand-based and structure-based approaches.

  2007cited by this paper
• hERG channel trafficking: novel targets in drug-induced long QT syndrome.

  2007cited by this paper
• Identification of IKr and Its Trafficking Disruption Induced by Probucol in Cultured Neonatal Rat Cardiomyocytes

  2007cited by this paper
• Co-chaperone FKBP38 Promotes HERG Trafficking*

  2007cited by this paper
• Cardiac Glycosides as Novel Inhibitors of Human Ether-a-go-go-Related Gene Channel Trafficking

  2007cited by this paper
• Drug‐induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine

  2006cited by this paper
• hERG potassium channels and cardiac arrhythmia

  2006cited by this paper
• Mechanisms of Pharmacological Rescue of Trafficking-defective hERG Mutant Channels in Human Long QT Syndrome*

  2006cited by this paper
• Combined hERG channel inhibition and disruption of trafficking in drug‐induced long QT syndrome by fluoxetine: a case‐study in cardiac safety pharmacology

  2006cited by this paper
• Chronic Inhibition of Cardiac Kir2.1 and hERG Potassium Channels by Celastrol with Dual Effects on Both Ion Conductivity and Protein Trafficking*♦

  2006cited by this paper
• The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.

  2006cited by this paper
• Protein trafficking abnormalities: a new mechanism in drug‐induced long QT syndrome

  2005cited by this paper
• Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking

  2005cited by this paper
• Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death.

  2005cited by this paper
• Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.

  2005cited by this paper
• Pentamidine reduces hERG expression to prolong the QT interval

  2005cited by this paper
• Basic mechanisms of cardiac impulse propagation and associated arrhythmias.

  2004cited by this paper
• Roles of K+ channels in regulating tumour cell proliferation and apoptosis

  2004cited by this paper
• Mechanisms of arsenic-induced prolongation of cardiac repolarization.

  2004cited by this paper
• Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.

  2004cited by this paper
• Drug binding to HERG channels: evidence for a ‘non‐aromatic’ binding site for fluvoxamine

  2003cited by this paper
• Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652

  2003cited by this paper
• Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

  2003cited by this paper
• Doxazosin Induces Apoptosis in Cardiomyocytes Cultured In Vitro by a Mechanism That Is Independent of &agr;1-Adrenergic Blockade

  2003cited by this paper
• Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing.

  2003cited by this paper
• Is Restoration of Intracellular Trafficking Clinically Feasible in the Long QT Syndrome?:

  2003cited by this paper
• Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERG

  2003cited by this paper
• Interaction with GM130 during HERG Ion Channel Trafficking

  2002cited by this paper
• The Binding Site for Channel Blockers That Rescue Misprocessed Human Long QT Syndrome Type 2 ether-a-gogo-related Gene (HERG) Mutations*

  2002cited by this paper
• HERG K+ channel, a regulator of tumor cell apoptosis and proliferation.

  2002cited by this paper
• Functional Up-regulation of HERG K+ Channels in Neoplastic Hematopoietic Cells*

  2002cited by this paper
• Molecular and cellular mechanisms of cardiac arrhythmias.

  2001cited by this paper
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

  2000cited by this paper
• A structural basis for drug-induced long QT syndrome.

  2000cited by this paper
• Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate

  2000cited by this paper
• Blocker protection in the pore of a voltage-gated K+ channel and its structural implications

  2000cited by this paper
• Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT Syndrome

  1999cited by this paper

• Predictive value of the hERG assay for anticipating the arrhythmogenic potential of new drugs.

  2026cites this paper
• Quercetin is a foe in the heart by targeting the hERG potassium channel

  2024cites this paper
• hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560

  2024cites this paper
• Parent and Metabolite Concentration-QT Modeling to Evaluate QT-Interval Prolongation at Savolitinib Therapeutic Doses

  2021cites this paper
• ANK2 functionally interacts with KCNH2 aggravating long QT syndrome in a double mutation carrier.

  2019cites this paper
• Ion Channel Trafficking in the Heart

  2018cites this paper
• Inhibition of Histone Deacetylases Induces K+ Channel Remodeling and Action Potential Prolongation in HL-1 Atrial Cardiomyocytes

  2018cites this paper
• Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders.

  2017cites this paper
• A novel inhibitor of active protein kinase G attenuates chronic inflammatory and osteoarthritic pain

  2017cites this paper
• Fluconazole-induced long QT syndrome via impaired human ether-a-go-go-related gene (hERG) protein trafficking in rabbits

  2016cites this paper
• Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.

  2016cites this paper
• Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide

  2015cites this paper
• Lead Discovery and Lead Modification

  2015cites this paper
• Discovery and preclinical development of new antibiotics

  2014cites this paper
• Down-regulation of ether-a-go-go-related gene potassium channel protein through sustained stimulation of AT1 receptor by angiotensin II.

  2014cites this paper
• Herg K+ Channel-Dependent Apoptosis and Cell Cycle Arrest in Human Glioblastoma Cells

  2014cites this paper
• Allitridin Reduces IKr Current by Disrupting the Trafficking of Human Ether-à-Go-Go-Related Gene Channels

  2014cites this paper
• Acquired (Drug-Induced) Long and Short QT Syndromes

  2013cites this paper
• Mechanisms of zolpidem‐induced long QT syndrome: acute inhibition of recombinant hERG K+ channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells

  2013influential citation
• Cardiac ion channel trafficking defects and drugs.

  2013cites this paper
• Inhibitors of hERG Channel Trafficking

  2013cites this paper
• MiR-17-5p Impairs Trafficking of H-ERG K+ Channel Protein by Targeting Multiple ER Stress-Related Chaperones during Chronic Oxidative Stress

  2013cites this paper
• Identification and functional characterization of the novel human ether-a-go-go-related gene (hERG) R744P mutant associated with hereditary long QT syndrome 2.

  2012cites this paper
• Trafficking of Intermediate (KCa3.1) and Small (KCa2.x) Conductance, Ca2+‐Activated K+ Channels: a Novel Target for Medicinal Chemistry Efforts?

  2012cites this paper
• Role of ion transport in control of apoptotic cell death.

  2012cites this paper
• Exploring Polypharmacology Using a ROCS-Based Target Fishing Approach

  2012cites this paper
• Molecular determinants of hERG potassium channel inhibition by disopyramide.

  2012cites this paper
• Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: a long-term follow-up.

  2012cites this paper
• A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP

  2012cites this paper
• Pharmacogenomics and Nanotechnology Toward Advancing Personalized Medicine

  2012cites this paper
• Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: part 2.

  2012cites this paper
• Synthesis and SAR studies of benzimidazole derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Focus to detune hERG inhibition

  2011cites this paper
• hERG Potassium Channels in Drug Discovery and Development

  2011cites this paper
• Hirsutenone directly blocks human ether-a-go-go related gene K+ channels.

  2011cites this paper
• Molecular Determinants of HERG Potassium Channel Inhibition by Disopyramide

  2011cites this paper
• Population Pharmacokinetic and Concentration—QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies

  2011cites this paper
• Optical Action Potential Screening on Adult Ventricular Myocytes as an Alternative QT-screen

  2011cites this paper
• hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine

  2011influential citation
• Novel roles for hERG K+ channels in cell proliferation and apoptosis

  2011cites this paper
• Assessing a Drug’s Proarrhythmic Liability: An Overview of Computer Simulation Modeling, Nonclinical Assays, and the Thorough QT/QTc Study

  2011cites this paper
• Ion channel trafficking: a new therapeutic horizon for atrial fibrillation.

  2010cites this paper
• Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine

  2010cites this paper
• ESCRT-dependent targeting of plasma membrane localized KCa3.1 to the lysosomes.

  2010cites this paper
• Current world literature.

  2004cites this paper